A high disease prevalence, the presentation in older age, a frequently slowly progressing course of disease, and high costs make diagnosis and therapy of prostate cancer a special challenge for urologists.
Effective prevention of the disease may help to resolve some of the problems mentioned above. Two randomised, controlled studies prove that effective chemoprevention of prostate cancer is possible using 5-α reductase inhibitors (finasteride, dutasteride) (LoE 1) both in individuals at low and those at high risk developing prostate cancer. Furthermore, there is evidence that other compounds, e.g. selective estrogen receptor modulators (SERMs), non-steroidal anti-inflammatory drugs (NSAIDs) and statins might also be effective. This review investigates potential risks and benefits of chemoprevention including a consideration of health economic aspects. The authors conclude that chemoprevention in a high risk cohort using 5-α reductase inhibitors is a viable option and may even be cost effective. In consequence, the options of chemoprevention in prostate cancer should be further explored in an open and unbiased way.
Written by:
Schmitz-Dräger BJ, Schöffski O, Marberger M, Sahin S, Schmid HP. Are you the author?
Urologie, Schön Klinik Nürnberg/Fürth, Urologie 24, c/o Europa-Allee 1, 90763, Fürth, Germany.
Reference: Recent Results Cancer Res. 2014;202:79-91.
doi: 10.1007/978-3-642-45195-9_10
PubMed Abstract
PMID: 24531781
UroToday.com Prostate Cancer Section
